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SMOKING—Patient-Reported Outcomes
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CONSUMER PERCEPTION OF SELF-AID MATERIALS IN OVER-
THE-COUNTER NICOTINE PATCH
Shi CW, Zhu SH, Jain S, Becerra L, Ganiats T
UC San Diego, La Jolla, CA, USA
OBJECTIVES: Over-the-counter (OTC) nicotine patch products
contain self-aid materials as a surrogate for formal physician
counseling. Little is known about whether consumers utilize
these resources and what their perceptions are of these materi-
als. We undertook a study to explore this issue. METHODS:
Adult consumers (N = 155) of OTC nicotine patch from 30 retail
pharmacies in San Diego County were recruited to complete a
self-administered questionnaire two weeks after purchase. The
questionnaire asked participants in an open-ended format
whether they elected to use the enclosed CD-ROM, a self-aid
tool, and the reasons behind their decision. Immersion/crystal-
lization methods were used to extract major themes. Logistic
regression was performed to explore factors associated with CD-
ROM use. RESULTS: Of the 22% percent who used the CD-
ROM, 26% stated that the material was helpful. Among the
78% who did not use the CD-ROM, most believed the material
would not augment their knowledge or motivation for quitting.
Other reasons for not viewing the CD-ROM included having no
time or seen similar materials in the past, lost or cannot ﬁnd the
CD-ROM, and forgetting to use the material. Utilization of CD-
ROM was more likely among individuals who live with multi-
ple smokers, have poor self-rated health status, experience
side-effects with the patch, and believe the patch is inexpensive.
CONCLUSION: Although self-aid materials are included in 
each OTC nicotine patch package, few consumers utilize this
resource. Even among those who did review the material, few
found it helpful. The current material appears to have more
application for those with multiple impeding factors to quitting.
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OBJECTIVES: Benign prostatic hyperplasia (BPH) is a highly
prevalent condition, affecting more than 50% of men aged >60
years. Alpha1-adrenergic blockers (ABs) tamsulosin, alfuzosin,
doxazosin, and terazosin are commonly used pharmacologic
treatments for benign prostatic hyperplasia (BPH). However,
there are limited data on intra-class comparisons of ABs with
respect to treatment failure, particularly in the U.S. This study
aimed to assess the rate of treatment failure with tamsulosin
versus other ABs among patients with BPH in a U.S. setting.
METHODS: A retrospective database analysis was performed
using health care claims for patients with an ICD-9 diagnosis for
BPH between 1Q2000 and 3Q2005. Only patients, aged >35
years, newly initiated with AB therapy were included; those with
a history of prostate or urogenital disease were excluded. Treat-
ment failure was deﬁned as switching to another AB therapy or
undergoing BPH-related surgery. Time-to-treatment failure was
assessed using Kaplan-Meier survival analyses; Cox proportional
hazard regression models were used to control for differences in
baseline characteristics. Alfuzosin, introduced in 2004, was eval-
uated in an exploratory analysis with a shorter, 15-month
follow-up period. RESULTS: At baseline, patients receiving tam-
sulosin (n = 10,340) were younger and more likely to see urol-
ogists than those receiving doxazosin (n = 3088) or terazosin (n
= 2710) (p < 0.050 for all). Rates of treatment failure were lower
for patients receiving tamsulosin compared to those receiving
doxazosin and terazosin in the Kaplan-Meier analysis (p < 0.001
for both); multivariate Cox regression models conﬁrmed these
ﬁndings versus doxazosin (HR = 1.8, p < 0.001) and terazosin
(HR = 2.1, p < 0.001). Compared to tamsulosin, patients receiv-
ing alfuzosin (n = 608) were also at greater risk of treatment
failure (HR = 2.6, p < 0.001). CONCLUSION: Among the study
population, initial treatment with tamsulosin resulted in reduced
rate of treatment failure compared to doxazosin and terazosin.
Deﬁnitive conclusions for alfuzosin require studies with longer
follow-up periods.
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Takemoto SK1, Pinsky B1,Woodward RS2
1Saint Louis University, Saint Louis, MO, USA, 2University of New
Hampshire, Durham, NH, USA
OBJECTIVES: Estimates from transplant centers and clinical
trials indicate approximately 30% of kidney transplant recipi-
ents are poorly compliant to their immunosuppressive (IS)
regimen. This behavior may be the underlying cause of a large
fraction of late acute rejection episodes and graft loss. Here we
examine the survival and economic outcomes associated with
varying degrees of compliance. METHODS: Compliance was
deﬁned as a medication possession ratio (MPR: % days with
medication in a year according to pharmacy claim records sub-
mitted to Medicare) for 12,185 kidney recipients with at least 1
year of function, transplanted from 1998–2002 with data pro-
vided by the United States Renal Data System. Patient cohorts
were deﬁned by MPR quartiles (lowest <72%, median = 89%,
highest >96%). Reported costs are average accumulated
Medicare payments for IS, inpatient and outpatient medical care
after the transplant procedure. RESULTS: As expected, ﬁrst-year
IS costs were lowest for the low quartile ($5.0 K vs. $9.4–12.4
K for the higher quartiles). 3-year graft survival, conditional on
1-year function was 89, 89, 91 and 93% with increasing MPR
for the 4 quartiles (P by log rank <0.001). 20% (n = 1636) of
patients remained in the two lower quartiles and 7% (n = 532)
in the highest quartile for all three years of the study. Cost curves
indicate that although 3-year IS costs were $16.1 K higher for
patients persisting in the high quartile($32.0 vs $15.8 k), medical
costs were $27.2 K less than the lower MPR cohort patients
($31.8 vs 58.9 K). Logistic regression propensity analysis com-
paring the two cohorts indicate patients under age 25 (relative
risk = 1.60, 95% conﬁdence interval 1.01–2.52, P = 0.05), and
African Americans (1.74, 1.36–2.22, P < 0.001) were more likely
in the low MPR cohort. CONCLUSION: Examination of
Medicare claims indicates patients with persistent high IS com-
pliance, incurred 15% lower overall 3-year costs ($11.1 K) com-
pared to those persistently low. These results indicate excellent
immunosuppression compliance should be encouraged.
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